Financial Performance: Biofrontera Inc. reported a 15% increase in second-quarter revenues to $9.0 million and a 12% increase for the first half of 2025, totaling $17.7 million, despite a net loss of $5.3 million in Q2 due to higher legal costs and non-cash fluctuations.
Business Developments: The company has restructured its agreement with Biofrontera AG, acquiring U.S. rights to Ameluz® and RhodoLED®, along with an additional $11 million in funding, which is expected to enhance operational efficiency and sales effectiveness moving forward.
BFRI
$0.7349+Infinity%1D
Analyst Views on BFRI
Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.790
Low
3.00
Averages
6.00
High
9.00
Current: 0.790
Low
3.00
Averages
6.00
High
9.00
Roth Capital
Buy
upgrade
$8 -> $10
2025-06-30
Reason
Roth Capital
Price Target
$8 -> $10
2025-06-30
upgrade
Buy
Reason
Roth Capital raised the firm's price target on Biofrontera Inc. to $10 from $8 and keeps a Buy rating on the shares. The firm notes Biofrontera Inc. acquired full U.S. Ameluz and RhodoLED rights from former parent company Biofrontera AG, which, when combined with the $11M investment from existing institutional investors, funds Biofrontera Inc. to profitability.
Benchmark
Bruce Jackson
Buy
downgrade
$7
2025-05-19
Reason
Benchmark
Bruce Jackson
Price Target
$7
2025-05-19
downgrade
Buy
Reason
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
